Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06179888 · ClinicalTrials.gov registry record · Phase 2

Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma

A Phase 2 study of Multiple Myeloma, sponsored by National Cancer Institute (NCI).

Recruiting
Registry status
Phase 2
Development phase
78
Enrollment target
20
Study locations

NCT06179888: Recruiting Phase 2 study of Multiple Myeloma, sponsored by National Cancer Institute (NCI).

NCT06179888 is a Phase 2 study of Multiple Myeloma that is actively recruiting participants, run by National Cancer Institute (NCI). The registered enrollment target is 78 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (86% lower). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06179888, a Phase 2 study of Multiple Myeloma, is actively recruiting participants, sponsored by National Cancer Institute (NCI).

RECRUITING
Registry status
Phase 2
Development phase
78 participants
Enrollment target
20
Study locations

Study Summary

This phase II trial compares iberdomide maintenance therapy to disease monitoring for improving survival in patients who have received idecabtagene vicleucel (a type of chimeric antigen receptor T-cell \[CAR-T\] therapy) for multiple myeloma. The usual approach after treatment with idecabtagene vicleucel is to monitor the multiple myeloma without giving myeloma medications. There is currently no medication approved specifically for use after idecabtagene vicleucel treatment. Upon administration, iberdomide modifies the immune system and activates immune cells called T-cells, which could enhance the effectiveness of idecabtagene vicleucel. Iberdomide may keep multiple myeloma under control for longer than the usual approach (disease monitoring) after idecabtagene vicleucel, and may help multiple myeloma patients live longer.

Conditions Studied

Multiple Myeloma

Interventions

  • PROCEDURE Biospecimen Collection
  • PROCEDURE Bone Marrow Aspiration
  • PROCEDURE Bone Marrow Biopsy
  • PROCEDURE Computed Tomography
  • DRUG Iberdomide

Study Locations (20)

Iowa

  • UI Health Care Mission Cancer and Blood - Ankeny Clinic - Ankeny
  • UI Health Care Mission Cancer and Blood - West Des Moines Clinic - Clive
  • Iowa Methodist Medical Center - Des Moines
  • UI Health Care Mission Cancer and Blood - Des Moines Clinic - Des Moines
  • Mercy Medical Center - Des Moines - Des Moines
  • UI Health Care Mission Cancer and Blood - Laurel Clinic - Des Moines
  • UI Health Care Mission Cancer and Blood - Waukee Clinic - Waukee

Missouri

  • Siteman Cancer Center at Saint Peters Hospital - City of Saint Peters
  • Siteman Cancer Center at West County Hospital - Creve Coeur
  • Washington University School of Medicine - St Louis
  • Siteman Cancer Center-South County - St Louis
  • Siteman Cancer Center at Christian Hospital - St Louis

California

  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care - Irvine
  • Cedars Sinai Medical Center - Los Angeles
  • UC Irvine Health/Chao Family Comprehensive Cancer Center - Orange
  • University of California Davis Comprehensive Cancer Center - Sacramento

Georgia

  • Augusta University Medical Center - Augusta

Illinois

  • University of Illinois - Chicago

Mississippi

  • Baptist Memorial Hospital and Cancer Center-Desoto - Southhaven

Nebraska

  • Nebraska Medicine-Bellevue - Bellevue

Trial Details

FieldValue
Enrollment Target 78 participants
Start Date 2024-08-27
Est. Completion 2027-10-31
Phase Phase 2

Sponsor

National Cancer Institute (NCI)

3,257 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06179888

The ClinicalTrials.gov registry entry for NCT06179888 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (86% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.

NCT06179888 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Iowa, Missouri, California.

Frequently Asked Questions

What is clinical trial NCT06179888 about?

NCT06179888 is a clinical study titled "Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma". This phase II trial compares iberdomide maintenance therapy to disease monitoring for improving survival in patients who have received idecabtagene vicleucel (a type of chimeric antigen receptor T-cell \[CAR-T\] therapy) for multiple myeloma. The usual approach after treatment with idecabtagene vicl...

What is the current status of trial NCT06179888?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 78 participants. The study started on 2024-08-27. Estimated completion is 2027-10-31.

What conditions does trial NCT06179888 study?

This clinical trial studies the following conditions: Multiple Myeloma.

What interventions are being tested in trial NCT06179888?

The interventions under investigation include: Biospecimen Collection (PROCEDURE), Bone Marrow Aspiration (PROCEDURE), Bone Marrow Biopsy (PROCEDURE), Computed Tomography (PROCEDURE), Iberdomide (DRUG).

Who is sponsoring clinical trial NCT06179888?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06179888 being conducted?

This trial has 20 study locations across California, Georgia, Illinois, Iowa, Mississippi. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Myeloma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Related

Compare this shortlist side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.